Morgan Stanley Reiterates Equal-Weight on ACADIA Pharmaceuticals, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has reiterated an Equal-Weight rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and maintained a $30 price target.
August 04, 2023 | 1:29 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has reiterated an Equal-Weight rating on ACADIA Pharmaceuticals and maintained a $30 price target.
The news is directly about ACADIA Pharmaceuticals. Morgan Stanley's reiteration of an Equal-Weight rating and maintenance of a $30 price target suggests that they believe the stock is fairly valued at its current price. This is likely to have a neutral impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100